Prevention of Diseases Induced by Chlamydia Trachomatis

Not Applicable

Completed

• Conditions: Genital Chlamydia Trachomatis Infection
• Interventions: Other: Testing for Ct infection at the end of the study; Other: Testing for Ct infection immediately

• Registration Number: NCT02904811
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The main objective of the study is to determine whether early screening and treating young women (\<25 years of age) for genital Chlamydia Trachomatis (Ct) infection reduces the cumulative incidence of pelvic inflammatory disease (PID) over 24 months.

As secondary objectives, the study aims

* To determine the baseline prevalence and the incidence of Ct infection;

* To improve knowledge on natural history of Ct infection in young women such as the rate and timing of progression to PID (at the beginning of the infection, at the end, throughout the course of infection), as well as the incidence of reinfections with Ct;

* To investigate the relation between host immuno-genetic factors and the clearance, persistence and development of late complications (PID) as an explanation for the inter-individual heterogeneity in the susceptibility to and course of Ct infection.

Detailed Description

In this research project, the study aims to assess a screening strategy (early screening and treatment of Ct genital infection in young women to prevent complications) that may be implemented in the future if proved efficient 7 centers are involved in the enrollment (university health services), and 4 centers will participate in the study within the frame of the follow-up and final visit (hospital gynaecology departments).

Participants included will have to perform 4 self-taken vaginal samples linked to four online corresponding questionnaires, at different timeframes 6-month apart to each other (M0, M6, M12, M18). The first sampling (M0) will be performed at the university health service, this self-taken sampling could also be performed at home later in case of menstruation; the others (M6, M12, M18) will be performed at home (or at the university if problem of sampling kits receiving at home).

Participants will be randomly assigned to one of the two following arms:

* in the non-intervention arm, participants will follow current guidelines of Ct screening (i.e. opportunistic screening only in STI clinics for women aged less than 25 years old), and their samples will be tested for Ct at M18 by the NRC;

* in the intervention arm, analyses for Ct will be carried out immediately by the NRC.

A final visit with a hospital gynecologist is planned for all participants between M18 and M24 and aims at providing an extensive clinical examination to seek for potential signs of pelvic inflammatory disease and to treat participants if needed.

Based on all data collected on the electronic platform through questionnaires from the different visits, independent experts blinded on chlamydia status will assess PID status of all participants (no PID, probable PID, confirmed PID).

The duration of enrollment is planned for 36 months.

The duration of follow-up for each patient is 18 months to 24 months.

Study Timeline

• Study First Submitted: 2016-09-14
• Study First Submitted QC: 2016-09-16
• Study First Posted: 2016-09-19
• Study Start: 2017-01-10
• Primary Completion: 2022-11-15
• Study Completion: 2022-11-15
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-15
• Last Update Posted: 2023-03-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 1092

Inclusion Criteria

• female students visiting the preventive medical centers of universities or the Ct screening test centers who participate in the study;
• participate in or will participate in the "i-Share" cohort;
• aged between 18 to 24 years,
• had prior sexual relations,
• written informed consent signed,
• affiliated to the social security bodies.

Exclusion Criteria

• Known pregnancy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	Testing for Ct infection at the end of the study	Testing for Ct infection at the end of the study
Intervention group	Testing for Ct infection immediately	Testing for Ct infection immediately Participants will perform self-taken vaginal samples. The positive results for Ct will be examined and treated and their partner will also be informed to do so.

Primary Outcome Measures

Name	Time	Method
Cumulative incidence	At 24 months	Cumulative incidence of first PID

Secondary Outcome Measures

Name	Time	Method
Time of Ct infection progressing to PID	Up to 24 months
Proportion of Ct infection progressing to PID	Up to 24 months
Proportion of spontaneous resolution of Ct infections	Up to 24 months	Proportion of spontaneous resolution of Ct infections
Incidence of first Ct infection	Up to 24 months	Incidence of first Ct infection for negative participants at baseline
Incidence of reinfections	Up to 24 months	Incidence of reinfections
Duration of Ct infection	Up to 24 months

Trial Locations

Locations (1)

Université de Versailles Saint Quentin; 🇫🇷 Versailles, Saint-Quentin-en-Yvelines, France